Sanofi
Long

FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic

REGN,SNY: Sanofi
2019-03-11 15:45:00
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - PR Newswire
Beyond Technical Analysis

Declinazione di responsabilità